Austin neuromodulation startup raises $25M Series A for non-invasive ultrasound therapy

An Austin company developing non-invasive ultrasound neuromodulation therapies for immune-mediated diseases has raised a $25 million Series A, according to funding trackers covering the local market. The approach uses focused ultrasound to modulate nerve activity without surgery or implants, a category drawing renewed scientific and investor interest.

The raise lands amid a broader surge in Austin healthtech, where companies pulled in hundreds of millions across recent years and several health-focused startups have reached growth stage. Series A and Series B rounds have come to dominate deal counts in the city even as a handful of mega-rounds drive total dollar volume.

Why it matters

Medical-device and therapeutics bets are harder and slower than software, so a funded Austin neuromodulation company signals that the city's life-sciences base is deepening beyond digital health apps. It also adds clinical-stage diversity to a startup scene often defined by robotics, chips and enterprise software.

Austin's funding distribution skews toward growth-stage capital, with Series A and Series B rounds now dominating deal count.— Dealroom, Austin deep dive